Piribo: Financial Markets Research: Palatin Technologies' Bremelanotide, new publication announcement

Piribo, the online destination for business intelligence for the biotech and pharmaceutical industry, has now added a new report called “Financial Markets Research: Palatin Technologies' Bremelanotide - Competition and regulatory risk cloud potential”. http://www.piribo.com/publications/finance_investment/financial_markets_research_palatin_technologies_bremelanotide.html

Palatin Technologies' bremelanotide (PT-141) is a novel melanocortin receptor agonist that is believed to be the only agent currently in development for the treatment of both erectile dysfunction (ED) and female sexual dysfunction (FSD).

Highlights
While there would appear to be much potential for an agent that can improve libido in both male and female patients without acting directly on the vascular system, we believe that unclear efficacy of PTN's bremelanotide and substantial regulatory risk diminish the potential this agent in the treatment of male and female sexual dysfunction.Pending results from the two Phase IIb trials which are expected later this year, we forecast US bremelanotide revenues well below the blockbuster potential estimated by some Wall Street analysts.

Scope
- Explores the regulatory and commercial potential for PTN's bremelanotide, a novel agent in development for male and female sexual dysfunction
- Interviews with 7 urologists familiar with bremelanotide and its clinical data and potential for the treatment of male and female sexual dysfunction
Reasons to Purchase
- Understand the commercial potential for Palatin Technologies' Bremelanotide through in-depth analysis based on interviews with leading experts
- Anticipate likely changes in the future market dynamics for erectile dysfunction therapies if approval of bremelanotide occurs

Contents
Summary
Palatin Technologies
Erectile Dysfunction
Factors Affecting The Potential For Bremelanotide
Bremelanotide Forecast
Appendix

“Financial Markets Research: Palatin Technologies' Bremelanotide - Competition and regulatory risk cloud potential” is available from Piribo. For more information go to: http://www.piribo.com/publications/finance_investment/financial_markets_research_palatin_technologies_bremelanotide.html

Piribo Product ID: DAT547

About Piribo.
Piribo (http://www.piribo.com) is a UK-based independent online store supplying business information on the pharmaceutical and biotechnology industries. The website now carries over 3,800 English language titles including, market reports, studies and books and is the UK’s largest online biopharma information store. Subscribers receive a free monthly newsletter and email alerts on new titles in their areas of interest. The company was established in 2004.